Stroke prevention in atrial fibrillation changes after dabigatran availability in China: The GLORIA-AF registry.
Chang Sheng MaLionel Riou FrançaShihai LuHans-Christoph DienerSergio J DubnerJonathan L HalperinQiang LiMiney PaquetteChristine TeutschMenno V HuismanGregory Yoke Hong LipKenneth J Rothmannull nullPublished in: Journal of arrhythmia (2020)
There was an increase in OAC and decrease in antiplatelet agent prescription since dabigatran availability in China. However, a large proportion of AF patients at risk for stroke remained untreated.
Keyphrases
- atrial fibrillation
- oral anticoagulants
- left atrial
- catheter ablation
- left atrial appendage
- direct oral anticoagulants
- heart failure
- end stage renal disease
- percutaneous coronary intervention
- ejection fraction
- chronic kidney disease
- newly diagnosed
- prognostic factors
- patient reported outcomes
- coronary artery disease
- acute coronary syndrome